atezolizumab
roche
['atezo']
#sitc22 updates: remarkable orr of 69% (9/13 pts) for oncolytic biotech's #pelareorep (oncolytic reovirus) +atezolizumab+chemo in pancreatic cancer, &gt;2x rate vs ~25% for historical controls warrants further evaluation in this setting
#pancreaticcancer #oncology #cancerresearch 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.